You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
獲中金看好信達生物(01801.HK)與藥明生物(02269.HK)漲近8%-10% 後者重越「紅底股」
中金最新報告認為,醫藥板塊調整後已具備配置價值,看好本港上市的藥明生物(02269.HK)及信達生物(01801.HK)等。 信達生物三連升,股價承昨天重越10天及50天線勢,今天進一步升破20天及百天線(73.15元及75.3元),最高見76.85元(暫受制牛熊線77.36元),現報76.3元,續升7.8%,成交續增至1,162萬股。 藥明生物扭四連跌,股價由逾七個月低位反彈兼重越「紅底股」,午後高見102.7元,現報102.2元,反彈9.8%,為最傷藍籌,但成交未能配合僅2,707萬股,遠少於昨天成交量6,439萬股。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account